Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
Latest news
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P...
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...
Our attention has been drawn to the fraudulent activities of persons posing as recruitment agencies or Polpharma Biol...
Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge...
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward buil...
